Nasal Polyps - Pipeline Insight, 2024

This “Nasal Polyps - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Nasal Polyps pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Nasal Polyps: Understanding

Nasal Polyps: Overview

Nasal polyps are benign inflammatory and hyperplastic outgrowths of the sinonasal mucosa. Their most common manifestation is in patients with chronic rhinosinusitis (CRS). For this reason, the term chronic rhinosinusitis with nasal polyposis (CRSw NP) is frequently used when discussing the topic of nasal polyps. However, they are also associated with aspirin-exacerbated respiratory disease (AERD), certain systemic vasculitis, and cystic fibrosis, among others. Polyposis is an end-stage manifestation of uncontrolled allergy, and management of extant polyposis is only the beginning of the process. Once the polyps have been addressed, local and systemic therapy aimed at controlling the underlying allergic etiology must be undertaken, or else they can rapidly recur. Presentation ranges from asymptomatic persons to patients with significant nasal obstruction, nasal and facial congestion, anosmia, ageusia, and rhinorrhea. These symptoms decrease the quality of life (QOL) of affectedindividuals.

The pathophysiology of nasal polyps can be varied. As the person age, there are a series of anatomical and functional changes that occur in the human body that lead to stasis of thick mucus and impaired clearance of irritants and biologic offenders (viruses, bacteria, and fungi), making patients more prone to develop polyps. These changes include decreased ciliary beat frequency with impaired mucociliary clearance, sinonasal mucosa atrophy with decreased vasculature, and diminished mucus secretion. These all potentially result in increased permeability of the epithelial basement membrane and distortion in the normal osmotic regulation between cells. Overall edema and resultant chronic inflammation results, leading to a localized increase in cell and tissue size. Hereditary factors have also been proposed (cystic fibrosis being but one of the hereditary factors, there are many others).

The predominant complaint is nasal obstruction, which is constant but will vary in severity with the size of the polyps. The obstruction may affect the quality of the voice. Examination of the nasal cavity either with anterior rhinoscopy or ideally with a rigid endoscope will readily enable visualisation of nasal polyps. Even in the absence of specialised equipment, the nose may be adequately examined with an aural speculum. The use of decongestants and local anaesthesia may improve examination but are not necessary in the presence of gross polyps. Imaging is of particular relevance if an encephalocele, fungal infection, or tumour is suspected. Intranasal corticosteroids such as budesonide, fluticasone propionate, and mometasone furoate have been shown to reduce polyp size. These should be used twice daily for several weeks before optimal effects can be appreciated. In contrast, for more severe disease, oral corticosteroids can be given; these should be provided in pulses and in a tapered way. There is no clear consensus among otolaryngologists regarding the maximum daily dose of systemic steroids, nor the tapering regimen. While antibiotics can be utilized for acute infection, the role of antibiotics in CRSw NP is controversial. There have been some reports of success in patients with CRSwNP with low IgE and neutrophilic diseases that receive macrolides. Current trials are underway to study further efficacy of this class ofantibiotics.

Nasal Polyps- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nasal Polyps pipeline landscape is provided which includes the disease overview and Nasal Polyps treatment guidelines. The assessment part of the report embraces, in depth Nasal Polyps commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nasal Polyps collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Nasal Polyps R&D. The therapies under development are focused on novel approaches to treat/improve Nasal Polyps.

Nasal Polyps Emerging Drugs Chapters

This segment of the Nasal Polyps report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nasal Polyps Emerging Drugs

Tezepelumab: Astra ZenecaTezepelumab is being developed by AstraZeneca in collaboration with Amgen as a potential first-in-class human monoclonal antibody that inhibits the action of TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and is critical in the initiation and persistence of allergic, eosinophilic and other types of airway inflammation associated with severe asthma. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles. Expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity. Blocking TSLP may prevent the release of pro-inflammatory cytokines by immune cells, resulting in the prevention of asthma exacerbations and improved asthma control. Tezepelumab acts at the top of the inflammation cascade and has the potential to help address a broad population of severe asthma patients irrespective of biomarker levels. Currently the drug is in Phase III stage of its development for the treatment of Chronic Rhinosinusitis with NasalPolyps.

Nasal Polyps: Therapeutic Assessment

This segment of the report provides insights about the different Nasal Polyps drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Nasal Polyps

• There are approx. 4+ key companies which are developing the therapies for Nasal Polyps. The companies which have their Nasal Polyps drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Nasal Polyps pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nasal Polyps: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nasal Polyps therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nasal Polyps drugs.

Nasal Polyps Report Insights

• Nasal Polyps Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Nasal Polyps Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Nasal Polyps drugs?
• How many Nasal Polyps drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nasal Polyps?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nasal Polyps therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Nasal Polyps and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AstraZeneca
• KeyMed Biosciences

Key Products

• CM-310
• Tezepelumab

This product will be delivered within 1-3 business days.